Ulka N. Vaishampayan, MBBS, FAB

Articles

Dr. Vaishampayan on the Design of the PROBE Trial in RCC

May 13th 2022

Ulka Nitin Vaishampayan, MBBS, discusses the design of the phase 3 PROBE trial in advanced renal cell carcinoma.

Dr. Vaishampayan on the Utility of FGFR Inhibitors in Urothelial Cancer

December 8th 2021

Ulka Nitin Vaishampayan, MBBS, discusses the utility of FGFR inhibitors in ​metastatic urothelial cancer.

Dr. Vaishampayan on the Future Directions for Second-Line Treatment in Urothelial Cancer

November 23rd 2021

Ulka Nitin Vaishampayan, MBBS, discusses future directions for second-line treatment in urothelial cancer.

Dr. Vaishampayan on the Expanding Role of TKI/Immunotherapy Combinations in mRCC

November 6th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the expanding role of TKI/immunotherapy combinations in metastatic renal cell carcinoma.

Dr. Vaishampayan on the Safety of Tivozanib Versus Sorafenib in RCC

September 15th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the safety of tivozanib versus sorafenib in advanced renal cell carcinoma.

Dr. Vaishampayan on the Potential of Tivozanib in Advanced RCC

September 9th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the potential of tivozanib in advanced renal cell carcinoma.

Dr. Vaishampayan on the Need to Develop Novel Therapies in mRCC

September 3rd 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the need to develop novel therapies for patients with metastatic renal cell carcinoma.

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC

August 27th 2020

Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of axitinib and pembrolizumab in advanced renal cell carcinoma.